Alan Joslyn - Net Worth and Insider Trading

Alan Joslyn Net Worth

The estimated net worth of Alan Joslyn is at least $0 dollars as of 2024-06-08. Alan Joslyn is the Director of Synergy Pharmaceuticals Inc and owns about 0 shares of Synergy Pharmaceuticals Inc (SGYPQ) stock worth over $0. Details can be seen in Alan Joslyn's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Alan Joslyn has not made any transactions after 2015-09-11 and currently still holds the listed stock(s).

Transaction Summary of Alan Joslyn

To

Alan Joslyn Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alan Joslyn owns 2 companies in total, including Oragenics Inc (OGEN) , and Synergy Pharmaceuticals Inc (SGYPQ) .

Click here to see the complete history of Alan Joslyn’s form 4 insider trades.

Insider Ownership Summary of Alan Joslyn

Ticker Comapny Transaction Date Type of Owner
OGEN Oragenics Inc 2016-06-06 director & CEO and President
SGYPQ Synergy Pharmaceuticals Inc 2018-06-16 director

Alan Joslyn Latest Holdings Summary

Alan Joslyn currently owns a total of 1 stock. Alan Joslyn owns 0 shares of Synergy Pharmaceuticals Inc (SGYPQ) as of September 11, 2015, with a value of $0.

Latest Holdings of Alan Joslyn

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SGYPQ Synergy Pharmaceuticals Inc 2015-09-11 0 0.01 0

Holding Weightings of Alan Joslyn


Alan Joslyn Form 4 Trading Tracker

According to the SEC Form 4 filings, Alan Joslyn has made a total of 0 transactions in Synergy Pharmaceuticals Inc (SGYPQ) over the past 5 years. The most-recent trade in Synergy Pharmaceuticals Inc is the sale of 13,754 shares on September 11, 2015, which brought Alan Joslyn around $99,304.

Insider Trading History of Alan Joslyn

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alan Joslyn Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Alan Joslyn Ownership Network

Ownership Network List of Alan Joslyn

No Data

Ownership Network Relation of Alan Joslyn

Insider Network Chart

Alan Joslyn Owned Company Details

What does Oragenics Inc do?

Who are the key executives at Oragenics Inc?

Alan Joslyn is the director & CEO and President of Oragenics Inc. Other key executives at Oragenics Inc include CFO & Secretary and Treasurer Janet Huffman , director & 10 percent owner Robert C Koski , and CFO & Secretary and Treasurer Michael O'keefe Sullivan .

Oragenics Inc (OGEN) Insider Trades Summary

Over the past 18 months, Alan Joslyn made no insider transaction in Oragenics Inc (OGEN). Other recent insider transactions involving Oragenics Inc (OGEN) include a net sale of 297,800 shares made by Robert C Koski , and a net sale of 3,500 shares made by Fred Telling .

In summary, during the past 3 months, insiders sold 0 shares of Oragenics Inc (OGEN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,463 shares of Oragenics Inc (OGEN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,463 shares.

Oragenics Inc (OGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Oragenics Inc Insider Transactions

No Available Data

Alan Joslyn Mailing Address

Above is the net worth, insider trading, and ownership report for Alan Joslyn. You might contact Alan Joslyn via mailing address: 39 Old Ridgebury Road, Danbury Ct 06810.

Discussions on Alan Joslyn

No discussions yet.